Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

BACKGROUND: Conventional criteria for tumor progression may not fully reflect the clinical benefit of immunotherapy or appropriately guide treatment decisions. The phase II IMvigor210 study demonstrated the efficacy and safety of atezolizumab, a programmed death-ligand 1-directed antibody, in patien...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Oncol
Autori principali: Necchi, A, Joseph, R W, Loriot, Y, Hoffman-Censits, J, Perez-Gracia, J L, Petrylak, D P, Derleth, C L, Tayama, D, Zhu, Q, Ding, B, Kaiser, C, Rosenberg, J E
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834063/
https://ncbi.nlm.nih.gov/pubmed/28950298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx518
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi